Doctor of Philosophy

Velo3D Expands Team in Europe to Support Growing Demand for Industrial Metal Additive Manufacturing

Retrieved on: 
Tuesday, August 24, 2021
Engineering, Technology, Manufacturing, Software, Steel, Hardware, EOS, Industry, University, Software, Sierra, Engineering, Lam Research, Cranfield University, Raytheon Technologies, Solution, GF, Master, Research, Honeywell, NYSE, Awareness, European Business Awards for the Environment, CEO, LinkedIn, 3D, Welding, Marine technology, Doctor of Philosophy, Technology, 3D printing

As global demand for top-quality 3D-printed industrial parts continues to grow, California-based Velo3D, Inc. , a leader in advanced additive manufacturing (AM) for high-value metal parts, has announced the appointment of two new Europe-based senior executives.

Key Points: 
  • As global demand for top-quality 3D-printed industrial parts continues to grow, California-based Velo3D, Inc. , a leader in advanced additive manufacturing (AM) for high-value metal parts, has announced the appointment of two new Europe-based senior executives.
  • "We're here to provide the European markets with a seamless transition to Velo3D's end-to-end manufacturing solution including its advanced support-free technology."
  • To learn more about how Velo3D empowers engineers and designers to imagine more and additively manufacture nearly anything, follow Velo3D on LinkedIn or visit velo3d.com .
  • Velo3D additive manufacturing solutions for 3D-printing high-value metal parts allow for previously impossible geometries, so businesses can make the mission-critical parts they need without compromise.

Shape Memory Medical Announces First Patient Enrollment in the AAA-SHAPE Netherlands Study

Retrieved on: 
Tuesday, August 24, 2021
Research, Surgery, Medical Devices, Hospitals, Clinical Trials, Cardiology, Health, General Health, Science, Blood, PMDA, Bachelor of Medicine, Bachelor of Surgery, Trial of the century, Memory, Auckland City Hospital, CE, Holden, Doctor of Philosophy, Abdominal aortic aneurysm, Neurovascular bundle, Learning, Shape-memory polymer, EVAR, Patient, AAA, MD, Medical imaging

The Dutch studys first procedure was performed by Professor Michel Reijnen, MD, PhD, vascular surgeon at Rijnstate Hospital in Arnhem, the Netherlands.

Key Points: 
  • The Dutch studys first procedure was performed by Professor Michel Reijnen, MD, PhD, vascular surgeon at Rijnstate Hospital in Arnhem, the Netherlands.
  • Ted Ruppel, President and Chief Executive Officer of Shape Memory Medical Inc. said, "We would like to congratulate Professor Reijnen and the clinical study team at Rijnstate Hospital for a successful first AAA-SHAPE case in the Netherlands.
  • The study will enroll up to 15 patients across three centers in the Netherlands, contributing to the AAA-SHAPE safety study which is also currently enrolling up to 15 patients in Auckland, New Zealand.
  • Shape Memory Medical Inc. is dedicated to developing innovative therapeutic solutions with its proprietary shape memory polymers.

The Prostate Cancer Foundation Challenges Americans To "Eat It To Beat It" During Prostate Cancer Awareness Month

Retrieved on: 
Tuesday, August 24, 2021
Well, Eat to the Beat, Prostate Cancer Foundation, Black, National Prostate Health Month, Cancer, Science, Man, Conditional sentence, Social media, Research, Disease, Doctor of Philosophy, Health, PCF, Death, Awareness, Prostate cancer, Risk, Food, Nutrition, Facebook, Health equity, Medicine, Dietary supplement, Medical imaging

LOS ANGELES, Aug. 24, 2021 /PRNewswire/ --The Prostate Cancer Foundation (PCF) challenges Americans to show their support for men affected by prostate cancer by taking a simple challenge to eat 30 healthy foods during Prostate Cancer Awareness Month in September.

Key Points: 
  • LOS ANGELES, Aug. 24, 2021 /PRNewswire/ --The Prostate Cancer Foundation (PCF) challenges Americans to show their support for men affected by prostate cancer by taking a simple challenge to eat 30 healthy foods during Prostate Cancer Awareness Month in September.
  • "Smart lifestyle modifications can help curtail the onset of cancer and itsprogression, including prostate cancer.
  • The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research.
  • The Prostate Cancer Foundation research now impacts more than 70 forms of human cancer by focusing onimmunotherapy, the microbiome, and food as medicine.

Seattle Co Develops Rapid Fingerprinting For COVID-19 Variants

Retrieved on: 
Tuesday, August 24, 2021
Microbiology, Journal, University, University of Washington Department of Bioengineering, SPC, Severe acute respiratory syndrome coronavirus 2, Genomics, ID, Infection, Diagnosis, Epsilon, Database, IDG, DNA, IEH, Doctor of Philosophy, European Journal of Clinical Microbiology & Infectious Diseases, Alpha, National, Laboratory, Vaccine, Principal, NIH, National Institutes of Health, COVID-19, Convalescence, MD

The test will 'fingerprint' at once all currently known COVID-19 variants of concern or interest, including Alpha, Beta, Gamma, Delta, Delta-plus, Epsilon, Lambda, etc, and offers the potential to detect the emergence of novel variants.

Key Points: 
  • The test will 'fingerprint' at once all currently known COVID-19 variants of concern or interest, including Alpha, Beta, Gamma, Delta, Delta-plus, Epsilon, Lambda, etc, and offers the potential to detect the emergence of novel variants.
  • "Rapid and comprehensive detection of the current and newly emerging viral variants will be invaluable for real-time surveillance of the COVID-19 pandemic and elucidation of the risks of infection in vaccinated, convalescent, and non-immunized individuals."
  • The rapid field-deployable test that is being developed with NIH support will detect the presence of mutations without the need for sequencing, by using multi-band dipstick DNA chromatography.
  • The rapid SARS-CoV-2 fingerprinting test will be simple and require a standard, broadly available thermocycler instrument.

Sciton's mJOULE™ Innovation Reaches Canada

Retrieved on: 
Tuesday, August 24, 2021
Industry, HERO, Face, Population, Ageing, Skin, Light, Acne, BBL, Health, Time, IPL, Risk, Patient, Hyperpigmentation, Doctor of Philosophy, Elective surgery, Chicago Innovation Awards, Technology, Pigment, Pharmaceutical industry, Medical imaging

TORONTO, Aug. 24, 2021 /PRNewswire/ -- Sciton Inc. , a leading manufacturer of medical and aesthetic lasers and light source technologies based in Palo Alto, California, announces the launch of its latest platform, mJOULE, in Canada.

Key Points: 
  • TORONTO, Aug. 24, 2021 /PRNewswire/ -- Sciton Inc. , a leading manufacturer of medical and aesthetic lasers and light source technologies based in Palo Alto, California, announces the launch of its latest platform, mJOULE, in Canada.
  • "Today we further that mission by extending the mJOULE platform to Canada, a burgeoning aesthetic market which has gained tremendous momentum over the past few years.
  • The mJOULE dual modality platform features BBL HERO and MOXI technologies, which were created in response to a changing market which desires less time consuming treatments, yet equally strong outcomes.
  • Sciton operates on a worldwide basis with direct sales teams in the United States, Canada, Australia, United Kingdom, Ireland, Japan and distributor partners in more than 45 countries.

New Study Indicates WW Works Regardless of Life Stressors, Including COVID-19 Pandemic

Retrieved on: 
Tuesday, August 24, 2021
COVID, Program, Life, Sleep, Anxiety, Control, Weight loss, Obesity, Doctor of Philosophy, Health, WW International, NASDAQ, Food, PubMed, Weight Watchers, News, COVID-19, Animal

"Regardless of where we are in the pandemic, these findings are incredibly relevant, because we know that life will always present its stressors and that can sometimes derail our focus on health and wellness," said WW Chief Scientific Officer Gary Foster, PhD.

Key Points: 
  • "Regardless of where we are in the pandemic, these findings are incredibly relevant, because we know that life will always present its stressors and that can sometimes derail our focus on health and wellness," said WW Chief Scientific Officer Gary Foster, PhD.
  • The real-world analysis of 1.5 million WW digital members is the largest study of a digital weight management program.
  • The results will be published in the September 2021 print issue of Obesity and are funded by WW International1.
  • WW (formerly Weight Watchers) is a human-centric technology company powered by the world's leading commercial weight management program.

NCSBN Elects National Leadership and Considers New Business with its Members at its 2021 Annual Meeting

Retrieved on: 
Tuesday, August 24, 2021
FAAN, Adoption, GLOBE, District, Leadership, Policy, NRB Network, Director, Doctor of Philosophy, CLC, RN, MSM, Maryland Board of Public Works, National Council of State Boards of Nursing, Board, National Council, FRE, Nursing, Education, Virginia Board of Health, CNE, MSN, Next Generation, CSAC, Medicine

Chicago, Aug. 24, 2021 (GLOBE NEWSWIRE) -- The National Council of State Boards of Nursing (NCSBN), www.ncsbn.org , met virtually Aug. 18-19, 2021, to consider pertinent association business with its members.

Key Points: 
  • Chicago, Aug. 24, 2021 (GLOBE NEWSWIRE) -- The National Council of State Boards of Nursing (NCSBN), www.ncsbn.org , met virtually Aug. 18-19, 2021, to consider pertinent association business with its members.
  • Delegates demonstrated visionary leadership in the adoption of revised NCSBN Model Act and Rules and the Next Generation NCLEX test design.
  • There are three exam user members and 27 associate members that are either NRBs or empowered regulatory authorities from other countries or territories.
  • The statements and opinions expressed are those of NCSBN and not individual members.

Terrestrial Energy Celebrates 100th Addition to Ontario Team

Retrieved on: 
Tuesday, August 24, 2021
Industry, Hatch, BWXT, Fourth generation, IMSR, Integral Molten Salt Reactor, Engineering, GLOBE, Ontario Power Generation, McMaster University, Nuclear energy, SMR, Efficiency, Small modular reactor, Doctor of Philosophy, Terrestrial Energy, Generation, Investment, Review, Energy, Canadian Nuclear Safety Commission, National Nuclear Laboratory, Safety, CNSC, Chalk River, Candu Energy Inc., CEO, Power plant engineering, NRC, Â, Water, Climate change, Technology, Westinghouse, Lithium, Fossil fuel, Renewable energy

Terrestrial Energy is actively recruiting for 27 positions and anticipates adding 80 more engineers and scientists to its Oakville operation over the next 12 months.

Key Points: 
  • Terrestrial Energy is actively recruiting for 27 positions and anticipates adding 80 more engineers and scientists to its Oakville operation over the next 12 months.
  • Terrestrial Energy represents world-leading technology that can make a major contribution to averting climate change globally, said Simon Irish, CEO of Terrestrial Energy.
  • The Terrestrial Energy IMSR is one of three SMRs being considered for deployment at Ontario Power Generations Darlington Nuclear Generating Station, and it is the only Canadian technology candidate.
  • Terrestrial Energy is a developer of Generation IV advanced nuclear power plants that use its proprietary Integral Molten Salt Reactor (IMSR) technology.

Novan Appoints Tomoko Maeda-Chubachi, MD, PhD, MBA as Chief Medical Officer

Retrieved on: 
Tuesday, August 24, 2021
Company, Atopic dermatitis, Private Securities Litigation Reform Act, Annual report, Infection, Hair loss, U.S. Securities and Exchange Commission, NO, Technology, Medicine, GLOBE, Association, Leadership, SB206, BOTE, Security (finance), Doctor of Philosophy, Molluscum contagiosum, NDA, Forward-looking statement, Inflammation, Psoriasis, MBA, Eli Lilly and Company, Pemphigus, File, Safety, Osaka University, Risk, NCE, Failure, Patient, GlaxoSmithKline, Compliance, Biological functions of nitric oxide, New chemical entity, FDA, GSK, COVID-19, Eli Lilly, Pfizer, Dermatology, Management, Medical device, Pharmaceutical industry

DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the appointment of Tomoko Maeda-Chubachi, MD, PhD, MBA as Chief Medical Officer. Dr. Maeda-Chubachi has served as Novan’s Senior Vice President, Medical since March of 2021 and Vice President, Medical Dermatology since joining the Company in September of 2017.

Key Points: 
  • Dr. Maeda-Chubachi has served as Novans Senior Vice President, Medical since March of 2021 and Vice President, Medical Dermatology since joining the Company in September of 2017.
  • With the leadership of Dr. Maeda-Chubachi as our Chief Medical Officer, I believe we are well-positioned to continue advancing our current development programs, unlock additional pipeline opportunities and build value for all stakeholders.
  • Prior to joining the Company, Dr. Maeda-Chubachi served as senior medical director at GlaxoSmithKline (GSK), leading clinical development projects for psoriasis, atopic dermatitis, pemphigus, and androgenic alopecia.
  • The recently observed data from the positive B-SIMPLE4 trial gives me great confidence as we work towards a potential NDA filing and potential approval for the treatment of molluscum contagiosum, stated Dr. Maeda-Chubachi, Chief Medical Officer of Novan.

McQuade Center for Strategic Research and Development Enters Collaboration with Aché to Develop Potential Treatment for General Anxiety Disorder and Post-Traumatic Stress Disorder

Retrieved on: 
Tuesday, August 24, 2021
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Nephrology, Commercialization, LLC, CNS, Twitter, Innovation Unit, Maintenance, Cardiology, Tuberculosis, Research, Drug discovery, Cosmetics, National university, Doctor of Philosophy, Health, OAPI, Post-traumatic stress disorder, Heart, Mental health, Development, GAD, Creativity, LinkedIn, Patient, Plasma protein binding, PTSD, Pharmaceutical industry, Aché Laboratorios Farmaceuticos S.A., McQuade Center for Strategic Research and Development (MSRD), ACHé LABORATORIOS FARMACEUTICOS S.A., MCQUADE CENTER FOR STRATEGIC RESEARCH AND DEVELOPMENT (MSRD)

Therefore, medications with new mechanisms of action are needed with the potential to achieve better therapeutic responses.

Key Points: 
  • Therefore, medications with new mechanisms of action are needed with the potential to achieve better therapeutic responses.
  • We are absolutely thrilled with this collaboration with MSRD, a member of Otsuka, said Vnia Alcantara Machado, president, Ach.
  • We believe MSRDs expertise in early-stage programs and Otsukas global leadership position in CNS will be crucial in the development of Achs ACH000029 for GAD and PTSD.
  • Ach has a dedicated Innovation Unit focused on the research and development of new medicines, generics, and similar drugs.